Home
References
  1. Bailie GR, Eisele G, Liu L, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20:1110-1115.
  2. Hsu C-Y, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002;13(11):2783-2786.
  3. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995.
  4. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol. 2001;28(2 suppl 8):1-6.
  5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
  6. Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med. 2006;73(3):289-297.
  7. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S145.
  8. Cotran RS, Kumar V, Collins T. Robbins Pathologic Basis of Disease, 6th ed. Philadelphia: WB Saunders Company;1999.
  9. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutrition Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009;4(1):57-61.
  10. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV iron with Elevated Ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18:975-984.
  11. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(suppl 1):S4-S8.
  12. Eschbach JW. Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol. 2005;18:347-361.
  13. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis. 2007;49(6):736-743.
  14. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161-167.
  15. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm. Accessed September 28, 2010.
  16. National Comprehensive Cancer Network. Cancer- and chemotherapy-induced anemia. Version 2.2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed September 15, 2010.
  17. Data on file. AMAG Pharmaceuticals, Inc.
  18. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047.
  19. USRDS 2008 Annual Data Report. Projected counts of prevalent dialysis patients in 2009. Figure 2.2.
  20. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p6_comp_g8.htm. Accessed September 28, 2010.
  21. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006;1:S9-S18.
AMAG Signoff